NASDAQ : AMRN
$0.26 (1.92%)
NASDAQ
Aaron D. Berg
Biotechnology
Healthcare
AMRN
80
IE
USD
0.01
3.48
2.46
0.73
0.00
$213.65M
1.33
0.64
11.20
1.23
-$1.8
-$38.8M
-15.64%
-16.16%
-7.34%
-5.20%
-8.53
-0.12
-0.12
$2.00
$3.00
$1.50
2/5
18 Analysts
590.50%
-1.75
4/9
$446.37M
$645.76M
$196.35M
-$8.07M
$154.77M
0.72
-30.11
3.48
-7.34%
-7.76%
-11.93%
9.10%
668 days
| Name | Title |
|---|---|
| Aaron D. Berg | Chief Executive Officer, President & Director |
| Peter Fishman | Senior Vice President & Chief Financial Officer |
| David Keenan | Executive Vice President & Chief Operating Officer |
| Eric Boothe | Senior Vice President of Corporate Development |
| Jonathan N. Provoost | Executive Vice President, Chief Legal & Compliance Officer and Secretary |
| Steven Ketchum | Executive Vice President, President of Research & Development and Chief Scientific Officer |
No votes yet today — be the first to share your view!
About Amarin Corporation plc (NASDAQ:AMRN) Stock
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the develop ... ment and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
2026-07-15 08:00:00
DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report second quarter 2026 financial results and conduct a conference call on Wednesday, July 29, 2026.
Bears are Losing Control Over Amarin (AMRN), Here's Why It's a 'Buy' Now
2026-07-10 10:56:05
Amarin (AMRN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
2026-06-30 16:15:00
Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated Triglycerides Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated Triglycerides
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?
2026-06-12 10:41:14
Here is how Amarin (AMRN) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
2026-05-27 08:00:00
DUBLIN and BRIDGEWATER, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new data from a post hoc analysis of the REDUCE-IT® trial presented at the European Atherosclerosis Society (EAS) Congress 2026 in Athens, Greece.
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
2026-05-08 12:11:09
Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.
All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy
2026-05-05 13:01:08
Amarin (AMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Amarin's Q1 Loss Narrower Than Expected, Sales Increase Y/Y
2026-04-30 14:05:26
AMRN beats earnings and sales estimates as Vascepa sales rise and cost cuts take hold, while the partnered Europe strategy reshapes growth.
Frequently Asked Questions
What is the current Amarin Corporation plc (AMRN) stock price?
Amarin Corporation plc(NASDAQ:AMRN) stock price is $13.81 in the last trading session. During the trading session, AMRN stock reached the peak price of $20.9 while $12.96 was the lowest point it dropped to. The percentage change in AMRN stock occurred in the recent session was 1.92% while the dollar amount for the price change in AMRN stock was $0.26.
AMRN's industry and sector of operation?
The NASDAQ listed AMRN is part of Biotechnology industry that operates in the broader Healthcare sector.
Who are the executives of AMRN?
Aaron D. Berg
| Chief Executive Officer, President & Director
Peter Fishman
| Senior Vice President & Chief Financial Officer
David Keenan
| Executive Vice President & Chief Operating Officer
Eric Boothe
| Senior Vice President of Corporate Development
Jonathan N. Provoost
| Executive Vice President, Chief Legal & Compliance Officer and Secretary
How many employees does AMRN have?
Number of AMRN employees currently stands at 80. AMRN operates from One Central Plaza, Dublin, DU 2, IE.
Link for AMRN official website?
Official Website of AMRN is: https://www.amarincorp.com
How do I contact AMRN?
AMRN could be contacted at phone #353 1 669 9020 and can also be accessed through its website. AMRN operates from One Central Plaza, Dublin, DU 2, IE.
How many shares of AMRN are traded daily?
The average number of AMRN shares traded daily for last 3 months was 83.1K.
What is the market cap of AMRN currently?
The market value of AMRN currently stands at $285.63M with its latest stock price at $13.81